MedTrace Logo

A Clinical Study of GK02 in Malignant Ascites

NCT07378436 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-01-30

No results posted yet for this study

Summary

A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors.

The trial initially plans to enroll 9 subjects with malignant ascites caused by advanced solid tumors.

Conditions

  • Malignant Ascites Caused by Advanced Solid Tumors

Interventions

DRUG

GK02

Autologous tumor-reactive T cells

Sponsors & Collaborators

  • Beijing GoBroad Hospital

    collaborator OTHER

  • Beijing Geekgene Technology Co., LTD

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-16
Primary Completion
2026-12-17
Completion
2027-12-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07378436 on ClinicalTrials.gov